In vivo, oncolytic HSV-1 OV-IL15C, expressing human IL-15 and its receptor IL-15Rα, were demonstrated to have significant suppression of tumor growth and prolonged survival in glioma-bearing mice compared to a therapy using the same OV without IL-15/IL-15Rα gene insertion. Here, IL15RA is linked to glioma.